Skip to content

Study · Randomized controlled trial · n = 21 · 1997

4 results

A study of desmopressin and blood loss during spinal fusion for neuromuscular scoliosis: a randomized, controlled, double-blinded study.

Theroux MC, Corddry DH, Tietz AE, Miller F, Peoples JD, Kettrick RG

Anesthesiology1 Aug 1997Cited by 29 (Europe PMC)

PMID9286889 (opens in a new tab)DOI10.1097/00000542-199708000-00012 (opens in a new tab)PepBankPUB-09286889
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In children with severe cerebral palsy undergoing spinal fusion, intraoperative and postoperative estimated blood loss was similar with DDAVP and placebo.

    In plain wordsIn children with severe cerebral palsy undergoing spinal fusion, blood loss was similar with DDAVP and placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changeEstimated blood loss
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    0.3 microg/kg · infusionAs given in this study (human).

    Source sentences

    Summary
    Estimated blood loss (intraoperative and postoperative) and amount of packed erythrocytes transfused were similar for the DDAVP and placebo groups.
    4 context sentences
    Summary · context
    Therefore, this study was designed to examine the homeostatic effects of DDAVP in children with severe cerebral palsy undergoing spinal fusion.
    Summary · context
    A randomized, double-blinded, and placebo-controlled trial of DDAVP was designed to enroll 40 patients.
    Summary · context
    However, termination of the study was advised by the Institutional Review Board after 21 patients were enrolled.
    Summary · context
    The DDAVP group received 0.3 microg/kg DDAVP in 100 ml normal saline, and the placebo group received normal saline alone.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In children with severe cerebral palsy undergoing spinal fusion, packed erythrocyte transfusion amounts were similar with DDAVP and placebo.

    In plain wordsIn children with severe cerebral palsy undergoing spinal fusion, packed red blood cell transfusion amounts were similar with DDAVP and placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changePacked erythrocyte transfusion
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    0.3 microg/kg · infusionAs given in this study (human).

    Source sentences

    Summary
    Estimated blood loss (intraoperative and postoperative) and amount of packed erythrocytes transfused were similar for the DDAVP and placebo groups.
    4 context sentences
    Summary · context
    Therefore, this study was designed to examine the homeostatic effects of DDAVP in children with severe cerebral palsy undergoing spinal fusion.
    Summary · context
    A randomized, double-blinded, and placebo-controlled trial of DDAVP was designed to enroll 40 patients.
    Summary · context
    However, termination of the study was advised by the Institutional Review Board after 21 patients were enrolled.
    Summary · context
    The DDAVP group received 0.3 microg/kg DDAVP in 100 ml normal saline, and the placebo group received normal saline alone.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In children with severe cerebral palsy undergoing spinal fusion, factor VIIIC concentrations were significantly greater after DDAVP than after placebo.

    In plain wordsIn children with severe cerebral palsy undergoing spinal fusion, factor VIIIC concentrations were higher after DDAVP than after placebo.

    Peptide
    Desmopressin
    Outcome
    IncreaseFactor VIIIC concentration
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    0.3 microg/kg · infusionAs given in this study (human).

    Source sentences

    Summary
    Concentrations of both factor VIIIC and vWF were significantly greater after DDAVP infusion when compared with concentrations after placebo infusion.
    4 context sentences
    Summary · context
    Therefore, this study was designed to examine the homeostatic effects of DDAVP in children with severe cerebral palsy undergoing spinal fusion.
    Summary · context
    A randomized, double-blinded, and placebo-controlled trial of DDAVP was designed to enroll 40 patients.
    Summary · context
    However, termination of the study was advised by the Institutional Review Board after 21 patients were enrolled.
    Summary · context
    The DDAVP group received 0.3 microg/kg DDAVP in 100 ml normal saline, and the placebo group received normal saline alone.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In children with severe cerebral palsy undergoing spinal fusion, vWF concentrations were significantly greater after DDAVP than after placebo.

    In plain wordsIn children with severe cerebral palsy undergoing spinal fusion, vWF concentrations were higher after DDAVP than after placebo.

    Peptide
    Desmopressin
    Outcome
    Increasevon Willebrand factor concentration
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    0.3 microg/kg · infusionAs given in this study (human).

    Source sentences

    Summary
    Concentrations of both factor VIIIC and vWF were significantly greater after DDAVP infusion when compared with concentrations after placebo infusion.
    4 context sentences
    Summary · context
    Therefore, this study was designed to examine the homeostatic effects of DDAVP in children with severe cerebral palsy undergoing spinal fusion.
    Summary · context
    A randomized, double-blinded, and placebo-controlled trial of DDAVP was designed to enroll 40 patients.
    Summary · context
    However, termination of the study was advised by the Institutional Review Board after 21 patients were enrolled.
    Summary · context
    The DDAVP group received 0.3 microg/kg DDAVP in 100 ml normal saline, and the placebo group received normal saline alone.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.